Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | LIPC | P11150 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | LIPE | Q05469 | 1/20 | 0.47 |
| ▸ | ABHD16A | O95870 | 2/20 | 0.46 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7044272 | 0.88 | MGLL (0.69) | MGLLBCHELIPCACHELIPE | |
| SCHEMBL7046480 | 0.86 | ABHD16A (0.50) | MGLLLIPCLIPEABHD16AFAAH | |
| SCHEMBL7044396 | 0.84 | MGLL (0.71) | MGLLBCHELIPCACHELIPE | |
| SCHEMBL7152190 | 0.82 | MGLL (0.77) | MGLLBCHELIPCACHELIPE | |
| SCHEMBL2702338 | 0.80 | MGLL (0.55) | MGLLBCHELIPCACHELIPE | |
| SCHEMBL2701979 | 0.73 | MGLL (0.61) | MGLLBCHELIPCACHELIPE | |
| SCHEMBL7040935 | 0.73 | ABHD16A (0.68) | MGLLLIPCLIPEABHD16AFAAH | |
| SCHEMBL14446352 | 0.70 | PTPN5 (0.46) | — | |
| SCHEMBL7044818 | 0.70 | MGLL (0.55) | MGLLBCHELIPCACHELIPE | |
| SCHEMBL6551376 | 0.69 | MGLL (1.00) | MGLLBCHELIPCACHELIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236288-A1 | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-12-25 | — | — | US | claimed |
| US-20030236288-A1 | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-12-25 | — | — | US | disclosed |
| US-6596742-B1 | Inhibitory effect on the hormone-sensitive lipase, HSL. insecticides, controlling metabolism and multistage synthesis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236288-A1 | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | PNLIP, CEL, LIPE | MGLL 10/4885BCHE 626/4885LIPC 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.